Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (SULTAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03164655
Recruitment Status : Recruiting
First Posted : May 23, 2017
Last Update Posted : June 26, 2020
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Brief Summary:
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only colorectal metastases (CRLM) considered still non resectable after at least two months of systemic induction chemotherapy.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Drug: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil Phase 2

Detailed Description:
to compare the efficacy of CT intensification combining hepatic arterial infusion(HAI) oxaliplatin plus IV FOLFIRI plus targeted therapy (anti-epidermal growth factor receptor (EGFR) or bevacizumab) to conventional systemic CT alone plus targeted therapy (anti-EGFR or antiangiogenic antibody), in patients with liver-only CRLM not amenable to curative-intent resection (and/or ablation) after systemic induction CT in terms of conversion to complete (R0 R1) resection (or ablation) rate (CRR).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study Comparing Treatment Intensification With CIAH Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy
Actual Study Start Date : July 25, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HAI oxaliplatin combined with I.V. FOLFIRI + target therapy
  • HAI oxaliplatin 100 mg/m² on D1
  • I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT
  • modified FOLFIRI regimen without fluorouracil bolus
  • I.V. irinotecan 180 mg/m² D1
  • I.V. bolus 5-Fluorouracil (5-FU): 0
  • I.V. leucovorin 400 mg/m² in 2 hours D1
  • I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours
Drug: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h

Active Comparator: conventional systemic CT
  • Response to systemic induction CT
  • Toxicity and duration of the systemic induction CT
  • RAS status
  • Current guidelines/standard of care
Drug: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h




Primary Outcome Measures :
  1. Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM [ Time Frame: 6 months ]
    Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM confirmed by a systematic review of the surgical and pathological report by an independent committee blind to the treatment received



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed colorectal cancer (CRC), and radiologic or histologic proof of CRLM not amenable to a curative intent-treatment.
  2. At least two months of prior induction systemic CT with oxaliplatin and/or irinotecan combined with a fluoropyrimidine combined or not to a targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) for metastatic disease (patients ending their adjuvant chemotherapy after primary tumor resection since more than 6 months should also have received first-line chemotherapy for metastatic disease). Further systemic chemotherapy lines are allowed.
  3. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons, radiologists, interventional radiologists and medical oncologists). The panel will review the CT scan and MRI of the patients (weekly web conference). Non-resectability criteria (one of the following criteria):

    • Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible
    • and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e., tumor involvement of main portal right and left portal veins, of the three main hepatic veins, or of the retrohepatic vena cava)
    • and/or documented progressive disease on imaging (according to the RECIST v1.1) or doubling of serum levels of carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA 19-9) following ≥2 months of induction CT
  4. At least one measurable liver metastasis according to the RECIST v1.1
  5. Age ≥18 years
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  7. Normal liver function, i.e. bilirubin <1.5 times the upper limit of normal values (ULN), aminotransferases <5 ULN, alkaline phosphatase <5 ULN
  8. International normalized ratio (INR) <1.5 ULN
  9. Neutrophils >1500/mm³, platelets >100 000/mm³, hemoglobin >9 g/dL (transfusion allowed)
  10. Calculated creatinine clearance >50 mL/min (Cockcroft and Gault formula)
  11. Informed consent signed by the patient or his/her legal representative
  12. Patient affiliated to a social security regimen
  13. Potentially reproductive patients must agree to use an effective contraceptive method or practice adequate methods of birth control or practice complete abstinence while on treatment, and for at least 6 months after the last dose of study drug.
  14. Uracilemia <16 ng/ml

Exclusion Criteria:

  1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation), according to the local multidisciplinary team and/or the central review.
  2. Definitive anatomical contraindication to complete surgical resection (any of the following criteria):

    • More than two lesions in all liver segments
    • Bilobar liver metastasis and more than three lesions >3 cm in the hepatic lobe the least affected (i.e. the future remnant liver)
    • Bilobar liver metastasis and disease liver extend >50%
  3. Extrahepatic tumor disease (except ≤3 lung nodules <10 mm deemed amenable to curative-intent resection/thermoablation and non-resected primary tumor with no or mild symptoms)
  4. Patient with contraindication for trial drugs (investigators have to refer to drugs SmPC); contraindication limited to targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) is not an exclusion criteria
  5. Disease progression after FOLFOXIRI/FOLFIRINOX
  6. Sensory neuropathy ≥ grade 2 (National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0)
  7. If patients received bevacizumab, following non-inclusion criteria must be respected:

    • Proteinuria >1 g,
    • Gastro-intestinal fistulae or perforation,
    • Hypersensitivity to Chinese hamster ovary cell products or other human recombinant antibody,
    • Major surgery in the last 28 days.
  8. If patients received panitumumab, following non-inclusion criteria must be respected:

    • Interstitial lung disease,
    • Pulmonary fibrosis.
  9. Significant chronic liver disease (resulting in portal hypertension and/or liver insufficiency)
  10. Allergy to contrast media that cannot be managed with standard care
  11. Previous organ transplantation, HIV or other immunodeficiency syndromes
  12. Concomitant or past history of cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix
  13. Patients with clinically significant active heart disease or myocardial infarction in the last 6 months
  14. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments as uncontrolled intercurrent illness (for instance: active infection, active inflammatory disorders, inflammatory bowel disease, intestinal obstruction, uncontrolled hypertension systolic >15 and diastolic >9, symptomatic congestive heart failure…)
  15. Ionic disorders as:

    • Kalemia ≥1 x ULN
    • Magnesemia <0.5 mmol/L
    • Calcemia <2 mmol/L
  16. Patient with a dihydropyrimidine dehydrogenase (DPD) deficiency; Uracilemia ≥16 ng/ml, the test should be done for all patients before first 5-FU administration, according to "agence nationale de sécurité du médicament" (ANSM) communication regarding recommendation about high risk of no testing DPD in patient before 5-FU administration
  17. QT/QTc >450 msec for men and > 470 msec for women
  18. Concomitant intake of St. John's wort
  19. Patient already included in another clinical trial with an experimental treatment
  20. Pregnancy or lactation
  21. Patients deprived of liberty or under guardianship
  22. Patients unable to undergo medical monitoring test for geographical, social or psychological reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03164655


Contacts
Layout table for location contacts
Contact: Veronica Pezzella 0144230477 v-pezzella@unicancer.fr
Contact: Claire Jouffroy c-jouffroy@unicancer.fr

Locations
Layout table for location information
France
Ico Paul Papin Active, not recruiting
Angers, France
Centre Eugene Marquis Active, not recruiting
Rennes, France
Chp Saint Gregoire Active, not recruiting
Saint-Grégoire, France
Gustave Roussy Recruiting
Villejuif, France, 94
Contact: Valérie Boige, PU PH    33 (0)1 42 11 43 11    valerie.boige@gustaveroussy.fr   
Sponsors and Collaborators
UNICANCER
Investigators
Layout table for investigator information
Principal Investigator: Valérie Boige Gustave Roussy Villejuif
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT03164655    
Other Study ID Numbers: UCGI 30 - PRODIGE 53 SULTAN
2016-001493-15 ( EudraCT Number )
First Posted: May 23, 2017    Key Record Dates
Last Update Posted: June 26, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.
Access Criteria: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Leucovorin
Bevacizumab
Cetuximab
Panitumumab
Fluorouracil
Oxaliplatin
Irinotecan
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites
Molecular Mechanisms of Pharmacological Action